

Inhibitory role of AMP-activated protein kinase in necroptosis of HCT116 colon cancer cells with p53 null mutation under nutrient starvation

DAN-DIEM THI LE*, SAMIL JUNG*, NGUYEN THI NGOC QUYNH, ZOLZAYA SANDAG, BEOM SUK LEE, SUBEEN KIM, HYE GYEONG LEE, HYOJEONG LEE and MYEONG-SOK LEE

Department of Biological Science, Sookmyung Women's University, Seoul 04310, Republic of Korea

Received May 30, 2018; Accepted October 12, 2018

DOI: 10.3892/ijo.2018.4634

Abstract. Simultaneous induction of other types of programmed cell death, alongside apoptosis, in cancer cells may be considered an attractive strategy for the development of more effective anticancer therapies. The present study aimed to investigate the role of AMP-activated protein kinase (AMPK) in nutrient/serum starvation-induced necroptosis, which is a programmed form of necrosis, in the presence or absence of p53. The present study detected higher cell proliferation and lower cell death rates in the HCT116 human colon cancer cell line containing a p53 null mutation (HCT116 p53^{-/-}) compared with in HCT116 cells harboring wild-type p53 (HCT116 p53^{+/+}), as determined using a cell viability assay. Notably, western blot analysis revealed a relatively lower level of necroptosis in HCT116 p53^{-/-} cells compared with in HCT116 p53^{+/+} cells. Investigating the mechanism, it was revealed that necroptosis may be induced in HCT116 p53^{+/+} cells by significantly increasing reactive oxygen species (ROS) and decreasing mitochondrial membrane potential (MMP), whereas little alterations were detected in HCT116 p53^{-/-} cells. Unexpectedly, a much lower level of ATP was detected in HCT116 p53^{-/-} cells compared with in HCT116 p53^{+/+} cells. Accordingly, AMPK phosphorylation on the Thr172 residue was markedly increased

in HCT116 p53^{-/-} cells. Furthermore, western blot analysis and ROS measurements indicated that AMPK inhibition, using dorsomorphin dihydrochloride, accelerated necroptosis by increasing ROS generation in HCT116 p53^{-/-} cells. However, AMPK activation by AICAR did not suppress necroptosis in HCT116 p53^{+/+} cells. In conclusion, these data strongly suggested that AMPK activation may be enhanced in HCT116 p53^{-/-} cells under serum-depleted conditions via a drop in cellular ATP levels. In addition, activated AMPK may be at least partially responsible for the inhibition of necroptosis in HCT116 p53^{-/-} cells, but not in HCT116 p53^{+/+} cells.

Introduction

In recent decades, apoptosis has been targeted as a therapeutic strategy to induce cancer cell death; therefore, several currently available anticancer drugs are designed to activate the apoptotic pathway directly or indirectly. However, numerous cancer cell types have acquired resistance to apoptosis by altering apoptosis-associated signaling pathways (e.g., loss of caspase 3), which has been a major obstacle to traditional chemotherapy. Therefore, other types of programmed cell death (PCD) have been explored. Dysregulation of PCD may induce various diseases, including numerous types of cancer. Initially, cell death has traditionally been divided into two types: Regulated cell death, i.e., apoptosis, and unregulated and accidental cell death, i.e., necrosis. However, more recent work has led to further information regarding the concept of cell death. One conceptual alteration is that another type of necrosis has been identified, which is considered to be a type of PCD; this type of necrosis has been named necroptosis (1-4). Therefore, it has been accepted that two types of necrosis exist, unregulated necrosis and regulated necroptosis. The present study focused on targeting necroptosis as an alternative strategy for treating cancer.

Necroptosis is a caspase-independent form of cell death, which is morphologically characterized by a loss of physical integrity, including swelling of organelles, increase in cellular volume, disruption of plasma and mitochondrial membranes, and release of intracellular contents. The most well studied signaling pathway for the induction of necroptosis is tumor necrosis factor-mediated

Correspondence to: Professor Myeong-Sok Lee, Department of Biological Science, Sookmyung Women's University, 100 Cheongpa-ro 47-gil, Yongsan-gu, Seoul 04310, Republic of Korea
E-mail: mslee@sookmyung.ac.kr

*Contributed equally

Abbreviations: PCD, programmed cell death; MMP, mitochondrial membrane potential; ROS, reactive oxygen species; AMPK, AMP-activated protein kinase; DCFH-DA, 2',7'-dichlorodihydrofluorescein diacetate; DM, dorsomorphin dihydrochloride; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide

Key words: necroptosis, p53, AMP-activated protein kinase

necroptosis, which is mainly mediated by activation of three core regulators: Receptor-interacting serine/threonine protein kinase (RIP)1, RIP3 and mixed lineage kinase domain-like protein (MLKL) (1,5-9). These regulators form three complexes (membrane-bound complex I, complex II and necrosome) sequentially, by changing binding partners (1,5-7,10). Necroptosis can be induced by various types of stress, including extreme nutrient deficiency. Unlike normal cells, cancer cells require unusually large amounts of nutrients to support their uncontrolled growth and proliferation; therefore, they are more easily exposed to severe nutrient deficiencies compared with normal cells. However, many cancer cells develop tolerance and overcome nutrient limitations by increasing nutrient uptake through alterations in metabolic signaling pathways or by activating angiogenesis (11-16). Therefore, it is important to elucidate these mechanisms, in order to develop novel therapeutic approaches. Therefore, this study initially focused on p53 and AMP-activated protein kinase (AMPK), as they are well known to serve various important roles under nutrient-deprived conditions and are considered promising therapeutic targets for cancer treatment.

One of the most powerful tumor suppressors, p53, is considered an appealing target for effective cancer therapy. Notably, approximately half of human cancers are known to have defective p53 expression, and p53 has been reported to be involved in several types of cell death [e.g., apoptosis, caspase-independent apoptosis (CIA), autophagy-mediated cell death, necroptosis, entosis, anoikis, paraptosis, pyroptosis, ferroptosis, mitotic catastrophe and efferocytosis] (17). It is widely accepted that p53 sensitizes normal cells to stressful conditions, including nutrient starvation. Mutations or deletions of p53 in cancer cells may overcome cell death pathways; therefore, these cells may exhibit resistance to chemotherapeutic drugs. Considering its vital roles in the regulation of cell death in response to various stressors, determining the role of p53 in the regulation of necroptosis may present a novel therapeutic strategy for cancer treatment.

AMPK also serves several vital roles in the regulation of metabolism and energy homeostasis. Cellular stress, such as nutrient starvation, induces the activation of AMPK, which is important for restoring intracellular energy balance. Activated AMPK inhibits energy-consuming biosynthetic processes and activates ATP biosynthesis (18). The most well known function of AMPK is its involvement in autophagy, in which it directly or indirectly promotes autophagy. In normal cells, AMPK acts as a metabolic tumor suppressor protein by activating autophagy to remove damaged or unnecessary proteins and organelles (19-25). However, it also functions as an oncogenic protein by protecting cancer cells from cell death by supporting their uncontrolled growth and proliferation (22,26,27). In contrast to its well-known function in autophagy, few studies have reported on its role in necroptosis.

The present study aimed to determine how cancer cells evade necroptosis under nutrient starvation, and revealed that enhanced AMPK activation may suppress necroptosis in p53-null cells (p53^{-/-}) but not in wild type cells (p53^{+/+}) under the same conditions.

Materials and methods

Cell lines, cell culture and cell treatment. The colorectal carcinoma cell lines, HCT116 p53^{+/+} and HCT116 p53^{-/-}, were a gift from Dr B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA) (28). The cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (WelGENE, Inc., Gyeongsan, South Korea) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% Antibiotic-Antimycotic solution (cat. no. 15240-06; Gibco; Thermo Fisher Scientific, Inc.). Both cell lines were grown at 37°C in a humidified atmosphere containing 5% CO₂ and 95% air. Dorsomorphin dihydrochloride (DM; cat. no. sc-361173; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR; cat. no. BML-EI330; Enzo Life Sciences, Inc., Farmingdale, NY, USA) were used to inhibit and activate AMPK, respectively. Cells were treated with 0, 5 and 10 μ M DM for 48 h, or with 0, 75, 150 and 300 μ M AICAR for 48 h at 37°C.

Cell viability and proliferation analysis. Cell viability was analyzed using the Cell Viability, Proliferation & Cytotoxicity Assay kit (EZ-CYTOX, cat. no. EZ-3000; DoGenBio, Seoul, South Korea), according to the manufacturer's protocol, in three replicates. Briefly, HCT116 p53^{+/+} and HCT116 p53^{-/-} cells ($\sim 2 \times 10^4$ cells/well) were seeded in 96-well plates for 24 h, and the media were replaced with RPMI 1640 media with or without 10% FBS for 24, 48, or 72 h. Cell viability was evaluated by measuring absorbance at 450 nm using a Gemini XPA Microplate Reader. Cell proliferation was analyzed by Trypan blue (EBT-001; NanoEnTek, Inc., Seoul, South Korea) staining under the same conditions; 10 μ l cells ($\sim 10^5$ cells) and 10 μ l Trypan blue were mixed in 1.5 ml microcentrifuge tubes at room temperature and were then placed into an EVE™ cell counting slide (NanoEnTek, Inc.), in order to count the number of live or dead cells. Cell proliferation was determined by counting the number of live cells at various time points (0, 24, 48 and 72 h) after culturing in complete media (CM) or serum-starved media (SS). Morphological images of cells were captured using an optical microscope with IS capture software (KI-400F; Korea Lab Tech, Seongnam, South Korea) at x100 magnification.

Analysis of necroptosis, apoptosis and autophagy. Necroptosis, apoptosis and autophagy were detected using western blotting for the detection of the following corresponding biomarkers: Cyclophilin (Cyp)A and high mobility group box 1 (HMGB1) for necroptosis (29); cleaved poly (ADP-ribose) polymerase (PARP) for apoptosis; and p62/sequestome 1 (SQSTM1) and microtubule-associated protein 1A/1B-light chain 3 (LC3) for autophagy. Necroptosis was also analyzed using the Green Fluorescent Protein-Certified Apoptosis/Necrosis Detection kit (cat. no. ENZ-51002; Enzo Life Sciences, Inc.), according to the manufacturer's protocol. This kit contained 7-amino-actinomycin D (7-AAD) and Annexin V, which were used to detect necroptosis and apoptosis, respectively.

Western blotting. HCT116 p53^{+/+} and HCT116 p53^{-/-} cells ($\sim 5 \times 10^6$ /ml) were centrifuged, (Smart R17; Hanil Scientific,

Inc., Gimpoo, South Korea) at 3,000 x g for 3 min at 4°C, washed in ice-cold PBS and lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris, pH 7.5; 48 mM NaCl; 1% Triton X-100 and 1 mM EGTA) with 0.5 mM Na_3VO_4 , 1 mM DTT and 1 μl premade protease inhibitor cocktail III (cat. no. P-1512; AG Scientific, Inc., San Diego, CA, USA)/ml RIPA solution. Protein concentration was quantified using a protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and 10 or 30 μg protein was loaded into each lane. Subsequently, proteins were separated by 10 or 12% SDS-PAGE and were then transferred onto an Immobilon-P® polyvinylidene fluoride transfer membrane (cat. no. IPVH00010; EMD Millipore, Billerica, MA, USA). Membranes were then blocked using 5% skimmed milk in PBS for 30-60 min at 20-25°C, and incubated overnight at 4°C with the primary antibodies. After washing with Tris-buffered saline containing 1% Tween-20 (cat. no. T1027; Biosesang, Seongnam, Korea), membranes were incubated with the corresponding secondary antibodies: Anti-rabbit (cat. no. 7074S, 1:5,000; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-mouse (cat. no. sc-516102, 1:5,000; Santa Cruz Biotechnology, Inc.) and anti-goat (cat. no. sc-2020, 1:5,000; Santa Cruz Biotechnology, Inc.). Immunodetection was performed using the PowerOpti-ECL western blotting detection reagent (cat. no. LR01-02; BioNote, Inc., Hwaseong, South Korea). The antibodies used in this study were as follows: Mouse monoclonal anti-p53 (cat. no. sc-126, 1:10,000; Santa Cruz Biotechnology, Inc.), rabbit monoclonal anti-AMPK α (cat. no. 2603P, 1:3,000) and anti-phosphorylated (p)-AMPK α (Thr172) (cat. no. 2535S, 1:3,000) (both Cell Signaling Technology, Inc.), rabbit polyclonal anti-CypA (cat. no. BML-SA296, 1:3,000), rabbit anti-HMGB1 (1:3,000, cat. no. ALX-210-964) (both Enzo Life Sciences, Inc.), rabbit polyclonal anti-PARP (cat. no. 9542S, 1:3,000), rabbit polyclonal anti-p62/SQSTM1 (cat. no. 5114, 1:3,000) (both Cell Signaling Technology, Inc.), mouse monoclonal anti-LC3 (cat. no. ALX-803-082, 1:2,500; Enzo Life Sciences, Inc.) and mouse monoclonal anti- β -actin (cat. no. sc-47778, 1:5,000; Santa Cruz Biotechnology, Inc.). β -actin was used as a loading control. To measure the extracellular levels of necroptosis biomarkers (CypA and HMGB1), 80 μl media were collected from 10 ml cell culture media and mixed with 20 μl 5X SDS-PAGE loading buffer (cat. no. S2002; Biosesang), of which 20 μl was separated by 12% SDS-PAGE and underwent western blotting. The results of western blot analysis were semi-quantified using ImageJ software (version 1.51u; <https://imagej.nih.gov/ij/>) supplied by the National Institutes of Health (Bethesda, MD, USA) and relative intensity compared with β -actin is presented in the bar graphs.

Measurement of reactive oxygen species (ROS). HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were cultured in RPMI media with or without 10% FBS for 24, 48 or 72 h. The cells were then collected in 15 ml conical tubes by centrifugation at ~200 x g for 2 min. Subsequently, ~5x10⁴ cells/50 μl PBS were added to each well of a 96-well plate and 50 μl 200 μM 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA; cat. no. D399; Invitrogen; Thermo Fisher Scientific, Inc.) was added into each well using a multichannel-pipette (PIPETMAN; Gilson Incorporated, Middleton, WI, USA), in order to achieve a final

concentration of 100 μM DCFH-DA. ROS levels were detected by measuring fluorescence at an excitation wavelength of 485 nm and an emission wavelength of 535 nm every 5 min for 30 min with a Gemini XPA microplate reader.

Measurement of mitochondrial membrane potential (MMP). MMP was assessed using a Mito-ID Membrane Potential Cytotoxicity kit (cat. no. ENZ-51019; Enzo Life Sciences, Inc.), according to the manufacturer's protocol. Briefly, HCT116 p53^{+/+} and HCT116 p53^{-/-} cells (~2x10⁵ cells/well) were cultured in 96-well plates (BD Falcon; BD Biosciences, Franklin Lakes, NJ, USA) in RPMI media with or without 10% FBS for 48 or 72 h. Subsequently, Mito-ID membrane potential dye loading solution was added to each well and was incubated for 3 h at room temperature. MMP was assessed by measuring the resulting fluorescence with a Gemini XPA microplate reader, at an excitation wavelength of 480 nm and an emission wavelength of 590 nm.

Measurement of cellular ATP levels. Cellular ATP levels were measured using the Luminescent ATP Detection Assay kit (cat. no. ab113849; Abcam, Cambridge, MA, USA), according to the manufacturer's protocol. Briefly, HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were seeded at ~2x10⁴/well in 96-well plates for 24 h. Subsequently, cells were incubated in RPMI media with or without 10% FBS and were cultured for 24 h. Detergent solution (50 μl) was then added to each well and the plate was agitated for 5 min at 600-700 rpm in an orbital shaker, in order to lyse the cells. Subsequently, 50 μl reconstituted substrate solution was added and the plate was agitated for a further 5 min. After 10 min in the dark, cellular ATP levels were measured by detecting luminescence using the GloMax® Discover multimode microplate reader (Promega Corporation, Madison, WI, USA).

Statistical analysis. Data are presented as the means \pm standard deviation from three independent experiments. Statistical analysis was performed using Student's t-test to compare two different groups or one-way analysis of variance, followed by Bonferroni's multiple comparisons test, to compare multiple groups. SPSS statistics version 23 was used to analyze data (IBM Corporation, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Cell proliferation is increased and cell death is reduced in HCT116 p53^{-/-} human colon cancer cells under nutrient/serum starvation. To explore the effects of p53 on necroptosis under nutrient/serum starvation, the present study compared cell proliferation and cell death between HCT116 p53^{+/+} and HCT116 p53^{-/-} cells after culturing them in CM or SS for 24, 48 or 72 h. HCT116 p53^{-/-} cells exhibited a higher growth rate compared with HCT116 p53^{+/+} cells under both conditions (Fig. 1A). Cell images were also obtained under an optical microscope. Microscope images revealed that, in response to serum starvation, HCT116 p53^{+/+} cells stopped proliferating and exhibited the typical morphological alterations of cell death, including detachment from the bottom of the plate and generation of round-shaped, shrunk or swollen cells, whereas




Figure 1. Effects of p53 on the proliferation and viability of HCT116 cells under conditions of serum starvation. (A) HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were cultured in RPMI-1640 with or without serum for the indicated durations (0, 24, 48 and 72 h). Growth rates were compared by Trypan blue staining following an initial plating density of $\sim 10^6$ cells per 100-mm plate; cells were counted for 4 days. Data are presented as the means \pm standard deviation from three independent experiments. (B) HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were seeded at a density of $\sim 10^6$ cells/100-mm plate and were grown in RPMI-1640 media with or without serum. Morphological images were captured under an optical microscope at $\times 100$ magnification. (C) Viable cells were evaluated by measuring the absorbance at 450 nm. Data are presented as the means \pm standard deviation from three independent experiments. * $P < 0.05$. CM, complete media; SS, serum-starved media.

HCT116 p53^{-/-} cells exhibited far fewer morphological alterations, although proliferation was greatly decreased (Fig. 1B). The cell viability assay also revealed a lower level of cell growth and viability in HCT116 p53^{+/+} cells compared with HCT116 p53^{-/-} cells following serum deprivation for 24, 48 and 72 h (Fig. 1C). Taken together, these results suggested that p53 may suppress cell proliferation and enhance cell death under the stress of nutrient/serum starvation.

Necroptosis is reduced in HCT116 p53^{-/-} cells in response to nutrient/serum starvation. HCT116 p53^{-/-} cells exhibited reduced cell death under serum deprivation. To investigate whether loss of p53 exerts inhibitory effects on necroptosis, the extracellular levels of necroptosis biomarkers, CypA and HMGB1, were detected using western blotting after HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were grown in RPMI media with or without serum for 24, 48 and 72 h (Fig. 2). The export of both proteins into the extracellular media was significantly increased after 48 h serum starvation in both cell lines, indicating the induction of necroptosis (Fig. 2A and B). However, the extracellular levels were much higher for HCT116 p53^{+/+} cells than for HCT116 p53^{-/-} cells after 72 h, thus indicating that necroptosis was suppressed in HCT116 p53^{-/-} cells (Fig. 2A and B). In addition, PARP cleavage was increased in HCT116 p53^{+/+} cells compared with in HCT116 p53^{-/-} cells, thus suggesting that the loss of p53 suppressed apoptotic cell death, as well as necroptosis (Fig. 2A and B). The expression levels of p53 were decreased in a time-dependent manner in HCT116 p53^{+/+} cells under the conditions of serum starvation (Fig. 2A and B).

The induction of necroptosis and apoptosis in HCT116 p53^{+/+} and HCT116 p53^{-/-} cells was examined by confocal microscopy; 7-AAD and Annexin V staining were used to detect necroptosis and apoptosis, respectively (Fig. 2C and D). In response to serum starvation for 72 h, marked 7-AAD and Annexin V fluorescence was detected in both cell lines, thus indicating that necroptosis and apoptotic cell death pathways were induced; much higher levels of necroptosis and apoptosis were detected in HCT116 p53^{+/+} cells compared with HCT116 p53^{-/-} cells (Fig. 2C and 2D).

Taken together, these results suggested that the absence of p53 in HCT116 cells may suppress necroptosis to a higher degree than in p53^{+/+} cells under serum starvation.

Effects of p53 on mitochondria-mediated necroptosis under serum starvation. To determine the role of p53 in necroptosis, it was hypothesized that p53 may induce it by regulating mitochondrial functions, including the production of ROS, maintenance of the MMP, or generation of ATP. These functions are understood to be strongly associated with several types of cell death; very high levels of ROS, and low levels of MMP and ATP, are known to accelerate cell death pathways (30–39). Therefore, the present study detected the cellular levels of ROS and ATP, as well as the MMP, in HCT116 p53^{+/+} and HCT116 p53^{-/-} cells under serum starvation.

Cellular ROS levels were detected in HCT116 p53^{+/+} and HCT116 p53^{-/-} cells cultured in media with or without serum for various durations. The results revealed that there was no significant difference between the cell lines until 48 h (data not shown). However, ROS levels were significantly




Figure 2. Necroptosis is reduced in HCT116 p53^{-/-} cells under serum starvation. (A) HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were grown in CM or SS for 24, 48 and 72 h. Western blotting was performed to detect representative biomarkers: CypA and HMGB1 for necroptosis, and PARP for apoptosis. β-actin was used as a loading control. All experiments were performed independently at least three times and representative data are shown. (B) Western blotting was semi-quantified using ImageJ. *P<0.05. (C) Cells (2x10⁵) were cultured in CM or SS for 72 h after seeding in a 35-mm confocal dish. Cells were observed under a confocal microscope (magnification, x200) after staining with Annexin V-EnzoGold (enhanced Cyanine-3) to detect apoptosis (yellow staining) and (7-AAD) to detect necroptosis (red staining). (D) Results were semi-quantified using ImageJ. *P<0.05. 7-AAD, 7-aminoactinomycin D; CM, complete media; CypA, cyclophilin A; HMGB1, high mobility group box 1; PARP, poly (ADP-ribose) polymerase; SS, serum-starved media.




Figure 3. Effects of p53 on cellular levels of ROS and ATP, as well as the MMP, in response to serum starvation. HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were incubated in media with or without serum for the indicated durations, and (A) cellular levels of ROS, (B) MMP and (C) cellular levels of ATP were measured. Data are presented as the means ± standard deviation from three independent experiments. *P<0.05. CM, complete media; DCF, dichlorofluorescein; MMP, mitochondrial membrane potential; ROS, reactive oxygen species; SS, serum-starved media.

increased after 72 h in HCT116 p53^{+/+} cells, whereas they were slightly decreased in HCT116 p53^{-/-} cells (Fig. 3A). These data suggested that p53-mediated necroptosis, at least in part, may occur by increasing cellular ROS levels under serum starvation.

Another mitochondrial mediator of cell death, MMP, was also compared between HCT116 p53^{+/+} and HCT116 p53^{-/-} cells. Cells were grown in SS for 24, 48 and 72 h. MMP was markedly decreased after 72 h in HCT116 p53^{+/+} cells, whereas no significant difference was observed in HCT116 p53^{-/-} cells (Fig. 3B). These data indicated that p53 may induce necroptosis by decreasing MMP in response to serum starvation.

Notably, several types of cell death are accompanied by ATP depletion (40-43). Therefore, the effects of p53 on cellular ATP levels were assessed in response to serum starvation. The results indicated that ATP levels were decreased in both cell lines. However, it was unexpectedly observed that ATP levels were more markedly decreased in HCT116 p53^{-/-} cells, whereas they were only slightly reduced in HCT116 p53^{+/+} cells after 24 h (Fig. 3C).

Taken together, these findings supported the hypothesis that p53 may accelerate necroptosis, at least partially, by increasing ROS levels and decreasing MMP in HCT116 cells under serum starvation.




Figure 4. Negative effects of p53 on AMPK activation in response to serum starvation. (A) HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were grown in CM or SS for 24, 48 and 72 h. Western blotting was used to determine the expression levels of AMPK, p-AMPK (Thr172), CypA, p62/SQSTM1 and LC3. β -actin was used as a loading control. All experiments were performed independently at least three times and representative data are shown. (B) Western blots were semi-quantified using ImageJ. *P<0.05. The ratio of p-AMPK (Thr172) to total AMPK is shown as p-AMPK/AMPK. AMPK, AMP-activated protein kinase; CM, complete media; CypA, cyclophilin A; LC3, microtubule-associated protein 1A/1B-light chain 3; p, phosphorylated; SQSTM1, sequestome 1; SS, serum-starved media.

AMPK activation is increased in p53^{-/-} cells under serum starvation. It is well known that nutrient starvation (e.g., depletion of glucose, amino acids or serum) leads to decreased intracellular ATP levels and that further extreme depletion may eventually induce cell death. Based on the importance of cellular ATP levels with regards to cell survival, it was expected that ATP levels would be lower in HCT116 p53^{+/+} cells, due to the higher levels of necroptosis. However, the present data revealed that ATP levels were lower in HCT116 p53^{-/-} cells in both CM and SS (Fig. 3C). In addition, much higher levels of proliferation were detected in HCT116 p53^{-/-} cells compared with in HCT116 p53^{+/+} cells under serum starvation (Fig. 1). Therefore, it was hypothesized that ATP levels may be lower in p53^{-/-} cells due to uncontrolled rapid cell proliferation and growth, which may cause much higher consumption of ATP. ATP depletion is the main signal that induces AMPK activation by phosphorylation of Thr172 (44-46). The present study demonstrated that serum starvation markedly increased phosphorylation of AMPK at Thr172 in HCT116 p53^{-/-} cells compared with in HCT116 p53^{+/+} cells. Even though there was a slight variation in the expression levels of total AMPK (Fig. 4A and B), the ratio of p-AMPK (Thr172) to total AMPK (p-AMPK/AMPK) indicated the significant increase in levels of AMPK phosphorylation (Fig. 4B). Therefore, it was hypothesized that AMPK activation may be involved in necroptotic cell death in a p53-dependent manner in response to serum depletion.

A well-known function of activated AMPK is the induction of autophagy, as one of the master regulators. Accordingly, autophagy was analyzed by detecting two well-known biomarkers, p62/SQSTM1 and LC3. The results revealed that serum deficiency decreased the expression levels of p62/SQSTM1 and increased the conversion ratio of LC3-I to LC3-II in HCT116 p53^{-/-} and HCT116 p53^{+/+} cells, thus indicating autophagic induction (Fig. 4A and B). However, p62/SQSTM1 protein levels were decreased to a slightly higher level in HCT116 p53^{-/-} cells after 24 h (Fig. 4A and B).

In addition, the conversion ratio from LC3-I to LC3-II was also greater in HCT116 p53^{-/-} cells after 48 h (Fig. 4A and B). These data suggested that AMPK may be activated in HCT116 p53^{-/-} cells at a higher level compared with in HCT116 p53^{+/+} cells.

Taken together, these results indicated that AMPK activation was highly induced in p53^{-/-} compared with in p53^{+/+} cells, probably due to reduced ATP levels.

AMPK activation alleviates necroptosis in HCT116 p53^{-/-} cells but not in HCT116 p53^{+/+} cells under serum starvation. To investigate whether activated AMPK is responsible for the inhibition of necroptotic cell death in p53^{-/-} cells, the effects of AMPK activation on necroptosis were examined using an AMPK inhibitor and AMPK activator.

AMPK activity was suppressed using the potent and selective AMPK inhibitor, DM. HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were exposed to CM or SS accompanied by DM at various doses (0, 5 and 10 μ M) for 48 h (Fig. 5A and B). Phosphorylation of AMPK at residue Thr172 was significantly decreased following treatment with 5 and 10 μ M DM, thus indicating that AMPK activation was successfully inhibited (Fig. 5A and B). Notably, the export of CypA was markedly increased in HCT116 p53^{-/-} cells in response to DM, even in CM (Fig. 5A and B); in addition, no significant differences were detected in CypA export between HCT116 p53^{+/+} and HCT116 p53^{-/-} cells following DM treatment (Fig. 5A and B). These findings strongly suggested that serum starvation-induced AMPK activation effectively suppressed necroptosis in the p53^{-/-} cells.

Secondly, AMPK activation was enhanced by AICAR, which mimics the effects of AMP (21,47-49). HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were cultured in CM and SS with various concentrations of AICAR (75, 150 and 300 μ M) for 48 h (Fig. 5C and D). The results revealed that phosphorylation of AMPK at residue Thr172 was increased in HCT116 p53^{+/+} cells following AICAR treatment, thus indicating that AMPK activity was successfully enhanced (Fig. 5C and D). AMPK




Figure 5. AMPK activation alleviates necroptosis in HCT116 p53^{-/-} cells but not in HCT116 p53^{+/+} cells under serum starvation. HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were cultured in CM or SS for the indicated durations. Cells were treated with (A and B) 0, 5 and 10 μM DM for 48 h or (C and D) 0, 75, 150 and 300 μM AICAR for 48 h. (A and C) Lysates were obtained and analyzed by western blotting, in order to detect phosphorylation of AMPK on the Thr172 residue, and the expression levels of CypA and p53. β-actin was used as a loading control. (B and D) Western blotting results were semi-quantified using ImageJ. The experiment was performed independently at least three times and representative data are shown. *P<0.05. Numbers represent relative intensity versus β-actin. The ratio of p-AMPK (Thr172) to total AMPK is shown as p-AMPK/AMPK. AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK, AMP-activated protein kinase; CM, complete media; CypA, cyclophilin A; DM, dorsomorphin dihydrochloride; p, phosphorylated; SS, serum-starved media.

activation was consistently high in HCT116 p53^{-/-} cells even prior to AICAR treatment. AICAR treatment slightly increased CypA export into the extracellular media in HCT116 p53^{+/+} and HCT116 p53^{-/-} cells maintained in CM (Fig. 5C and D). Notably, extracellular CypA levels were not decreased but were markedly increased in HCT116 p53^{+/+} cells, whereas no alteration was detected in HCT116 p53^{-/-} cells under SS, indicating that enhanced AMPK activation by AICAR can inhibit necroptosis only in HCT116 p53^{-/-} cells (Fig. 5C and D). These findings strongly suggested that AMPK activation may suppress necroptosis only in p53^{-/-} cells in response to serum starvation.

The present study revealed that inhibition and activation of AMPK promoted necroptosis in HCT116 p53^{+/+} cells under serum starvation, in which p53 protein expression levels were increased (Fig. 5). This may be because abnormal AMPK activity triggered upregulation of p53 and induced necroptosis.

Taken together, these observations suggested that AMPK activation through phosphorylation of Thr172 enhanced

inhibition of necroptosis in p53^{-/-} cells, but not in p53^{+/+} cells, under nutrient/serum starvation.

AMPK inhibits necroptosis through the suppression of ROS generation in p53^{-/-} cells. To address how AMPK activation suppresses necroptosis in HCT116 p53^{-/-} cells, the effects of AMPK on cellular levels of ROS and ATP, and on the MMP, were assessed in HCT116 p53^{+/+} and HCT116 p53^{-/-} cells. The results indicated that AMPK inhibition by DM significantly increased ROS generation in HCT116 p53^{-/-} cells (Fig. 6A). However, no significant difference was detected in MMP between the HCT116 p53^{+/+} and HCT116 p53^{-/-} cells, thus indicating that reductions in MMP by AMPK inhibition are independent of p53 (Fig. 6B). Furthermore, DM reduced ATP levels more than SS alone in both cell lines; however, ATP levels were slightly higher in HCT116 p53^{-/-} cells compared with in HCT116 p53^{+/+} cells following DM treatment (Fig. 6C).




Figure 6. Inhibitory role of AMP-activated protein kinase on ROS generation in HCT116 p53^{-/-} cells in response to serum starvation. HCT116 p53^{+/+} and HCT116 p53^{-/-} cells were cultured in CM or SS for 24 or 48 h. Cells were treated with 10 μ M DM for the indicated durations, and (A) cellular ROS, (B) MMP and (C) ATP levels were measured. The experiment was performed independently at least three times and representative data are shown. *P<0.05. CM, complete media; DCF, dichlorofluorescein; DM, dorsomorphin dihydrochloride; MMP, mitochondrial membrane potential; ROS, reactive oxygen species; SS, serum-starved media.




Figure 7. Summary of the inhibitory role of AMPK in necroptosis in p53^{-/-} cells under the stressful condition of nutrient/serum starvation. Nutrient/serum depletion increased ROS generation, and decreased MMP and ATP levels in HCT116 p53^{+/+} cells, resulting in necroptosis. Notably, cellular ATP levels were markedly decreased in HCT116 p53^{-/-} cells at a much higher level, compared with in HCT116 p53^{+/+} cells. This may lead to increased phosphorylation of AMPK on residue Thr172; ultimately, activation of AMPK inhibited necroptosis by negatively regulating cellular ROS production. AMPK, AMP-activated protein kinase; MMP, mitochondrial membrane potential; ROS, reactive oxygen species.

Taken together, these data indicated that highly activated AMPK may be at least partially responsible for the inhibition of necroptosis via suppression of ROS generation in p53^{-/-} cells.

Discussion

Escape from cell death, particularly apoptosis, is a serious problem in current cancer research. Therefore, it might be considered an effective therapeutic strategy to trigger several types of cell death at the same time. The present study focused on necroptosis, in addition to apoptosis, with the eventual aim of identifying a novel class of combined targeted therapeutics. The present study revealed that AMPK serves a different role in the regulation of necroptosis in the presence and absence of p53. It was demonstrated that a much lower level of necroptosis was detected in p53^{-/-} cells, and serum starvation-induced necroptosis was suppressed by enhancing AMPK activation.

p53 is involved in the regulation of several types of cell death, including apoptosis, CIA, autophagy-mediated cell death, necroptosis, entosis, anoikis, paraptosis, pyroptosis, ferroptosis, mitotic catastrophe and efferocytosis (17). Among these types of cell death, several studies have reported vital roles for p53 in necroptosis. Tu *et al* demonstrated that p53

can activate necroptosis in response to ROS-induced DNA damage through the activation of the lysosomal cysteine protease, cathepsin Q (50). Furthermore, it has been suggested that p53 accumulates in the mitochondrial matrix, complexes with CypD, and induces necroptosis in response to oxidative stress (31,32). Vaseva *et al* suggested that p53 causes necroptosis by controlling the opening of the mitochondrial permeability transition pore (32). Montero *et al* reported that p53 triggers necroptosis by increasing PARP-1 activity, and inducing depletion of NAD and ATP (33). In spite of these studies, the role of p53 in necroptosis remains unclear and more information is required.

There are discordant results regarding the functions of p53 in cell death regulation. Different combinations of master regulators may explain it, each of which has various functions, such as AMPK. The present results revealed that serum starvation-induced AMPK activation suppressed necroptosis in p53^{-/-} cells but not in p53^{+/+} cells. In contrast to these data, two research groups proposed that AMPK induced necroptosis and apoptosis (51-53). For example, Koo *et al* suggested that AMPK activation, resulting from impaired mitochondrial oxidative phosphorylation, induces necroptosis in human lung epithelial cells (51). Other research

groups revealed that AMPK activation induces apoptosis in liver cells by activating signaling pathways, including c-Jun N-terminal kinase and caspase-3 (52,53). However, they did not consider the effects of p53 in their research. It has been reported that the metabolic environmental conditions and pathways that activate AMPK differentially regulate cell proliferation or viability in cancer and normal cells (19,54). Only a few studies have reported on the highly complex interrelationship between p53 and AMPK in cell death. For example, Okoshi *et al* proposed that AMPK activation induces p53-dependent apoptosis in response to energetic stress (53). Huang *et al* revealed that AMPK inhibition by DM induces apoptosis in skin cancer cells via a p53-dependent pathway (55). The same effect of DM was reported in human colorectal cancer cells, with regards to the induction of apoptosis and necroptosis (18). Lee *et al* also demonstrated that AMPK induces p53 acetylation via phosphorylation and inactivation of sirtuin 1 in liver cancer cells (56). In addition, p53 can regulate autophagy, even though its regulation is controversial, indicating an effect of p53 on AMPK (57-59). However, the exact mechanism underlying the interaction between p53 and AMPK remains elusive.

The present study demonstrated that autophagy was induced at a higher level in HCT116 p53^{-/-} cells, probably due to enhanced AMPK activation. Numerous studies have reported that autophagy protects cells from cell death under various types of cell death-inducing stress, such as anticancer treatment and severe nutrient starvation (60-62). These data suggested that increased activation of AMPK in HCT116 p53^{-/-} cells may induce higher levels of autophagy and eventually suppress other types of cell death in response to serum starvation; however, the association between autophagy and necroptosis requires further study.

RIP1-RIP3-MLKL is known to be a core signaling pathway in necroptosis. The RIP1-RIP3-MLKL-dependent necroptosis machinery may be considered a primary mechanism for suppressing tumorigenesis and cancer progression. Cancer cells may suppress necroptosis by downregulating or inducing functional mutations in RIP1, RIP3 and MLKL. Previous studies indicated that RIP1 expression levels are decreased in only a few cancer cells, whereas RIP3 expression is downregulated in numerous cancer cells (5,63-65). For example, HeLa cervical cancer cells are well known for their resistance to necroptosis, and they express normal levels of RIP1 but no RIP3 expression (66,67). Notably, HCT116 cells have also been reported to lack RIP3 protein (5,68). However, in the present study, HCT116 p53^{+/+} cells underwent necroptosis under the stress of serum starvation; therefore, it remains to be determined as to how HCT116 cells undergo necroptosis. Elucidating the mechanism underlying necroptosis will be of great interest.

In conclusion, the present study proposed a plausible model, in which activation of AMPK through phosphorylation of Thr172 may inhibit necroptosis in the absence of p53 in response to serum starvation (Fig. 7). This study proposed that AMPK may be a combined target to efficiently kill cancer cells with defective p53 under low-nutrient conditions. These data provided information regarding a signaling network between p53 and AMPK in necroptosis, which may be provoked in response to serum starvation.

Acknowledgements

The authors of this study are grateful to Dr. B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA) for generously donating the colorectal carcinoma cell lines, HCT116 p53^{+/+} and HCT116 p53^{-/-}, for use in the experiments.

Funding

The present study was supported by Sookmyung Women's University (2015).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

DDTL conducted the majority of the experiments, analyzed data and drafted the manuscript. SJ conceptualized the study, developed the general experimental design, analyzed data and revised the manuscript. NTNQ was involved in the use of ImageJ, statistical analysis and manuscript preparation. ZS assisted in developing the study design and preparing the manuscript. BSL contributed to confocal analysis and preparation of the manuscript. SK, HGL and HJL assisted in experimental preparation, cell culturing and maintenance, and preparation of manuscript. MSL made substantial contributions to conception and experimental design, revised the manuscript and gave final approval of the version to be published. All authors read and approved the manuscript and agree to be accountable for all aspects of this research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Pasparakis M and Vandenabeele P: Necroptosis and its role in inflammation. *Nature* 517: 311-320, 2015.
2. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H and Vandenabeele P: Regulated necrosis: The expanding network of non-apoptotic cell death pathways. *Nat Rev Mol Cell Biol* 15: 135-147, 2014.
3. Vandenabeele P, Galluzzi L, Vanden Berghe T and Kroemer G: Molecular mechanisms of necroptosis: An ordered cellular explosion. *Nat Rev Mol Cell Biol* 11: 700-714, 2010.
4. Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu R, Yuan J and Cuny GD: Structure-activity relationship study of novel necroptosis inhibitors. *Bioorg Med Chem Lett* 15: 5039-5044, 2005.

5. Moriwaki K, Bertin J, Gough PJ, Orlowski GM and Chan FK: Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. *Cell Death Dis* 6: e1636, 2015.
6. de Almagro MC and Vucic D: Necroptosis: Pathway diversity and characteristics. *Semin Cell Dev Biol* 39: 56-62, 2015.
7. Xu YZ, Kanagaratham C, Youssef M and Radzioch D: New Frontiers in Cancer Chemotherapy-Targeting Cell Death Pathways. In: *Cell Biology - New Insights*. Najman S (ed). IntechOpen, pp93-140, 2016.
8. Dondelinger Y, Hulpiau P, Saeys Y, Bertrand MJM and Vandenabeele P: An evolutionary perspective on the necroptotic pathway. *Trends Cell Biol* 26: 721-732, 2016.
9. Belizário J, Vieira-Cordeiro L and Enns S: Necroptotic Cell Death Signaling and Execution Pathway: Lessons from Knockout Mice. *Mediators Inflamm* 2015: 128076, 2015.
10. Chan FKM, Luz NF and Moriwaki K: Programmed necrosis in the cross talk of cell death and inflammation. *Annu Rev Immunol* 33: 79-106, 2015.
11. Avril T, Vauléon E and Chevet E: Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. *Oncogenesis* 6: e373, 2017.
12. Palorini R, Votta G, Pirola Y, De Vitto H, De Palma S, Airolti C, Vasso M, Ricciardiello F, Lombardi PP, Cirulli C, *et al*: Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis. *PLoS Genet* 12: e1005931, 2016.
13. Izuishi K, Kato K, Ogura T, Kinoshita T and Esumi H: Remarkable tolerance of tumor cells to nutrient deprivation: Possible new biochemical target for cancer therapy. *Cancer Res* 60: 6201-6207, 2000.
14. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, Ueno T, Ochiai A and Esumi H: Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. *Cancer Res* 67: 9677-9684, 2007.
15. Esumi H, Izuishi K, Kato K, Hashimoto K, Kurashima Y, Kishimoto A, Ogura T and Ozawa T: Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5'-AMP-activated protein kinase-dependent manner. *J Biol Chem* 277: 32791-32798, 2002.
16. Kim SM, Nguyen TT, Ravi A, Kubiniok P, Finicle BT, Jayashankar V, Malacrida L, Hou J, Robertson J, Gao D, *et al*: PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. *Cancer Discov* 8: 866-883, 2018.
17. Ranjan A and Iwakuma T: Non-Canonical Cell Death Induced by p53. *Int J Mol Sci* 17: 2068, 2016.
18. Liu X, Chhipa RR, Nakano I and Dasgupta B: The AMPK inhibitor compound C is a potent AMPK-independent antiangioma agent. *Mol Cancer Ther* 13: 596-605, 2014.
19. Hardie DG: AMPK and autophagy get connected. *EMBO J* 30: 634-635, 2011.
20. Luo Z, Zang M and Guo W: AMPK as a metabolic tumor suppressor: Control of metabolism and cell growth. *Future Oncol* 6: 457-470, 2010.
21. Mihaylova MM and Shaw RJ: The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nat Cell Biol* 13: 1016-1023, 2011.
22. Liang J and Mills GB: AMPK: A contextual oncogene or tumor suppressor? *Cancer Res* 73: 2929-2935, 2013.
23. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Violette B, *et al*: AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. *Cell Metab* 17: 113-124, 2013.
24. Hardie DG: AMP-activated protein kinase: An energy sensor that regulates all aspects of cell function. *Genes Dev* 25: 1895-1908, 2011.
25. Li W, Saud SM, Young MR, Chen G and Hua B: Targeting AMPK for cancer prevention and treatment. *Oncotarget* 6: 7365-7378, 2015.
26. Jeon SM, Chandel NS and Hay N: AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature* 485: 661-665, 2012.
27. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M and Esumi H: Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. *Oncogene* 21: 6082-6090, 2002.
28. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* 282: 1497-1501, 1998.
29. Christofferson DE and Yuan J: Cyclophilin A release as a biomarker of necrotic cell death. *Cell Death Differ* 17: 1942-1943, 2010.
30. Lin Y, Choksi S, Shen H-M, Yang Q-F, Hur GM, Kim YS, Tran JH, Nedospasov SA and Liu ZG: Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. *J Biol Chem* 279: 10822-10828, 2004.
31. Dashzeveg N and Yoshida K: Cell death decision by p53 via control of the mitochondrial membrane. *Cancer Lett* 367: 108-112, 2015.
32. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S and Moll UM: p53 opens the mitochondrial permeability transition pore to trigger necrosis. *Cell* 149: 1536-1548, 2012.
33. Montero J, Dutta C, van Bodegom D, Weinstock D and Letai A: p53 regulates a non-apoptotic death induced by ROS. *Cell Death Differ* 20: 1465-1474, 2013.
34. Tsujimoto Y and Shimizu S: Role of the mitochondrial membrane permeability transition in cell death. *Apoptosis* 12: 835-840, 2007.
35. Eguchi Y, Shimizu S and Tsujimoto Y: Intracellular ATP levels determine cell death fate by apoptosis or necrosis. *Cancer Res* 57: 1835-1840, 1997.
36. Tatsumi T, Shiraishi J, Keira N, Akashi K, Mano A, Yamanaka S, Matoba S, Fushiki S, Fliss H and Nakagawa M: Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. *Cardiovasc Res* 59: 428-440, 2003.
37. Liou G-Y and Storz P: Reactive oxygen species in cancer. *Free Radic Res* 44: 479-496, 2010.
38. Redza-Dutordoir M and Averill-Bates DA: Activation of apoptosis signalling pathways by reactive oxygen species. *Biochim Biophys Acta* 1863: 2977-2992, 2016.
39. Marchi S, Giorgi C, Suski JM, Agnoletto C, Bononi A, Bonora M, De Marchi E, Missiroli S, Patergnani S, Poletti F, *et al*: Mitochondria-ros crosstalk in the control of cell death and aging. *J Signal Transduct* 2012: 329635, 2012.
40. Fulda S: The mechanism of necroptosis in normal and cancer cells. *Cancer Biol Ther* 14: 999-1004, 2013.
41. Kaczmarek A, Vandenabeele P and Krysko DV: Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. *Immunity* 38: 209-223, 2013.
42. Dasgupta A, Nomura M, Shuck R and Yustein J: Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue. *Int J Mol Sci* 18: 23, 2016.
43. González-Juarbe N, Gilley RP, Hinojosa CA, Bradley KM, Kamei A, Gao G, Dube PH, Bergman MA and Orihuela CJ: Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. *PLoS Pathog* 11: e1005337, 2015.
44. Steinberg GR and Kemp BE: AMPK in Health and Disease. *Physiol Rev* 89: 1025-1078, 2009.
45. Oakhill JS, Chen Z-P, Scott JW, Steel R, Castelli LA, Ling N, Macaulay SL and Kemp BE: β -Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). *Proc Natl Acad Sci USA* 107: 19237-19241, 2010.
46. Yung MMH, Ngan HYS and Chan DW: Targeting AMPK signaling in combating ovarian cancers: Opportunities and challenges. *Acta Biochim Biophys Sin (Shanghai)* 48: 301-317, 2016.
47. Wang W, Yang X, López de Silanes I, Carling D and Gorospe M: Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. *J Biol Chem* 278: 27016-27023, 2003.
48. Grahame Hardie D: Regulation of AMP-activated protein kinase by natural and synthetic activators. *Acta Pharm Sin B* 6: 1-19, 2016.
49. Smith AC, Bruce CR and Dyck DJ: AMP kinase activation with AICAR simultaneously increases fatty acid and glucose oxidation in resting rat soleus muscle. *J Physiol* 565: 537-546, 2005.
50. Tu HC, Ren D, Wang GX, Chen DY, Westergard TD, Kim H, Sasagawa S, Hsieh JJD and Cheng EHY: The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. *Proc Natl Acad Sci USA* 106: 1093-1098, 2009.
51. Koo MJ, Rooney KT, Choi ME, Ryter SW, Choi AMK and Moon JS: Impaired oxidative phosphorylation regulates necroptosis in human lung epithelial cells. *Biochem Biophys Res Commun* 464: 875-880, 2015.
52. Meisse D, Van de Castele M, Beauloye C, Hainault I, Kefas BA, Rider MH, Foulle F and Hue L: Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. *FEBS Lett* 526: 38-42, 2002.

53. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A and Kizaki H: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. *J Biol Chem* 283: 3979-3987, 2008.
54. Ferretti AC, Tonucci FM, Hidalgo F, Almada E, Larocca MC and Favre C: AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation. *Oncotarget* 7: 17815-17828, 2016.
55. Huang SW, Wu CY, Wang YT, Kao JK, Lin CC, Chang CC, Mu SW, Chen YY, Chiu HW, Chang CH, *et al*: p53 modulates the AMPK inhibitor compound C induced apoptosis in human skin cancer cells. *Toxicol Appl Pharmacol* 267: 113-124, 2013.
56. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, Hardie DG, Ng IO and Ching YP: AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. *Cancer Res* 72: 4394-404, 2012.
57. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA and Kroemer G: Autophagy regulation by p53. *Curr Opin Cell Biol* 22: 181-185, 2010.
58. Scherz-Shouval R, Weidberg H, Gonen C, Wilder S, Elazar Z and Oren M: p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. *Proc Natl Acad Sci USA* 107: 18511-18516, 2010.
59. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M, Cecconi F, Tavernarakis N and Kroemer G: A dual role of p53 in the control of autophagy. *Autophagy* 4: 810-814, 2008.
60. Fitzwalter BE and Thorburn A: Recent insights into cell death and autophagy. *FEBS J* 282: 4279-4288, 2015.
61. Boya P, González-Polo R-A, Casares N, Perfettini J-L, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, *et al*: Inhibition of macroautophagy triggers apoptosis. *Mol Cell Biol* 25: 1025-1040, 2005.
62. Nikolettou V, Markaki M, Palikaras K and Tavernarakis N: Crosstalk between apoptosis, necrosis and autophagy. *Biochim Biophys Acta* 1833: 3448-3459, 2013.
63. Nagues AL, El Bouazzati H, Hétiuin D, Berthon C, Loyens A, Bertrand E, Jouy N, Idziorek T and Quesnel B: RIP3 is down-regulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. *Cell Death Dis* 5: e1384, 2014.
64. Koo G-B, Morgan MJ, Lee D-G, Kim W-J, Yoon J-H, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, *et al*: Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. *Cell Res* 25: 707-725, 2015.
65. Yang C, Li J, Yu L, Zhang Z, Xu F, Jiang L, Zhou X and He S: Regulation of RIP3 by the transcription factor Sp1 and the epigenetic regulator UHRF1 modulates cancer cell necroptosis. *Cell Death Dis* 8: e3084, 2017.
66. Su Z, Yang Z, Xie L, DeWitt JP and Chen Y: Cancer therapy in the necroptosis era. *Cell Death Differ* 23: 748-756, 2016.
67. Wang Z, Jiang H, Chen S, Du F and Wang X: The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. *Cell* 148: 228-243, 2012.
68. Brown MF, Leibowitz BJ, Chen D, He K, Zou F, Sobol RW, Beer-Stolz D, Zhang L and Yu J: Loss of caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis. *Cell Death Dis* 6: e1729, 2015.